PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete If Known	
Application Number	Not Yet Assigned
Filing Date	April 19, 2004
First Named Inventor	Daniel Gaudet
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	WIBL-P02-522

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/NR/	AA	US-4,636,465	01-13-1987	Itoh, et al	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
/NR/	AR	Gaudet, *et al.*, "Glycerol as a Correlate of Impaired Glucose Tolerance: Dissection of a Complex System by Use of a Simple Genetic Trait", *Am. J. Hum. Genet.* 66: 1558-1568 (2000).	
/NR/	AS	Sargent, *et al.*,"H. sapiens glycerol kinase gene deficiency locus", GenBank Accession Number X78211 (1994).	
/NR/	AT	Pelkonen, *et al.*, "Metabolism of Glycerol in Diabetes Mellitus", *Diabetologia* 3(1): 1-8 (1967).	
/NR/	AU	Rose and Haines, "Familial Hyperglycerolemia", *J. Clin. Invest.* 61: 163-170 (1978).	
/NR/	AV	Pettigrew, *et al.*, "Conserved Active Site Aspartates and Domain-Domain Interactions in Regulatory Properties of the Sugar Kinase Superfamily", *Archives of Biochemistry and Biophysics* 349(2): 236-245 (1998).	
/NR/	AW	Sjarif, *et al.*, "Clinical heterogeneity and novel mutations in the glycerol kinase gene in three families with isolated glycerol kinase deficiency", *J. Med. Genet.* 35(8): 650-656 (1998).	
/NR/	AX	Walker, *et al.*, "Mutations and Phenotype in Isolated Glycerol Kinase Deficiency", *Am. J. Hum. Genet.* 58: 1205-1211 (1996).	
/NR/	AY	Blomquist, *et al.*, "Glycerol kinase deficiency in two brothers with and without clinical manifestations", *Clin. Genet.* 50: 375-379 (1996).	
/NR/	AZ	Mahairas, G. *et al.*, "Sequence-Tagged Connectors: A Sequence Approach to Mapping and Scanning the Human Genome," *Proceedings of the National Academy of Sciences of the United States of America*, 96(17):9739-9744 (1999).	
/NR/	AR2	Mahairas *et al.*,HS_5333_B1_GO6_SP6E RPCI-11 Human Male BAC Library Homo sapiens genomic clone Plate+909 Col-11 Row=N, genomic survey sequence, EMBL Database [online], 1999 [retrieved on 2001-04-25]. Retrieved from the Internet <URL:http://srs.ebi.ac.uk/srs6bin/cgi-bin/wgetz?-id+b9841Gitof+-e+[EMBL:'AQ673121']> Accession Number AQ673121.	
/NR/	AS2	Hagström-Toft, E. *et al.*, "Lipolytic response during spontaneous hypoglycaemia in insulin-dependent diabetic subjects," *Hormone and Metabolic Research* 30(9):586-593 (1998).	

Examiner Signature	/Nora Rooney/	Date Considered	08/05/2007

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	Not Yet Assigned
Filing Date	April 19, 2004
First Named Inventor	Daniel Gaudet
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	WIBL-P02-522

/NR/	AT2	Sargent, C.A. *et al.*, "Five cases of isolated glycerol kinase deficiency, including two families: Failure to find genotype:phenotype correlation," *Journal of Medical Genetics* 37(6):434-441 (2000).	
/NR/	AU2	Sargent, C.A., Homo sapiens partial GK gene for glycerol kinase, exon 12 (glycerol kinase deficiency case), EMBL Database [Online], 1999 [retrieved on 2001-04-25]. Retrieved from the Internet <URL:http://srs.ebi.ac.uk/srs6bin/cgi-bin/wgetz?-id+b9841Gitof+-e+[EMBL:'AQ673121']> Accession Number HSA252563/AJ252563.	
/NR/	AV2	Schoonderwoerd K. *et al.*, "Enhanced Lipolysis of Myocardial Triglycerides During Low-flow Ischemia and Anoxia in the Isolated Rat Heart," *Basic Research in Cardiology* 84(2):165-173 (1989).	
/NR/	AW2	Uhal, B.D. and Longmore, W.J., "Altered Glycerol Metabolism in the Type II Pneumocyte Isolated from Streptozotocin-Diabetic and BB Wistar Spontaneously Diabetic Rats," *Federation Proceedings* 44(5):1606 (1985). Abstract 6992.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Nora Rooney/	Date Considered	08/05/2007

Attachment II

```
RESULT 29
AAQ53469
ID   AAQ53469 standard; DNA; 2106 BP.
XX
AC   AAQ53469;
XX
DT   25-MAR-2003  (revised)
DT   16-JUN-1994  (first entry)
XX
DE   Rat type I iodothyronine 5' deiodinase gene.
XX
KW   Type I; iodothyronine; 5'; deiodinase; 3' untranslated region;
KW   selenocysteine; transient expression assay; antibody; diagnosis;
thyroid;
KW   function; selenocysteine insertion sequence; reporter gene;
transfection;
KW   efficiency; promoter; ss.
XX
OS   Rattus rattus.
XX
FH   Key             Location/Qualifiers
FT   CDS             7. .780
FT                   /*tag=  a
FT                   /product= "5' deiodinase"
XX
PN   US5272078-A.
XX
PD   21-DEC-1993.
XX
PF   29-JAN-1992;   92US-00828790.
XX
PR   29-JAN-1991;   91US-00647657.
PR   03-SEP-1991;   91US-00757024.
XX
PA   (BGHM ) BRIGHAM & WOMENS HOSPITAL.
XX
PI   Berry MJ,  Larsen PR;
XX
DR   WPI; 1993-413408/51.
DR   P-PSDB; AAR44511.
XX
PT   DNA encoding the type I iodo-thyronine 5'-deiodinase and mutants of
this
PT   - has a seleno-cysteine site which may be used to study thyroid
hormone
PT   and in diagnosis of thyroid cancer.
XX
PS   Disclosure; Fig 1; 49pp; English.
XX
CC   This sequence encodes a rat type I iodothyronine 5' deiodinase.
This
CC   sequence was used as a probe in the isolation of the human type I
CC   iodothyronine 5' deiodinase gene. The isolated gene contains in the
3'
CC   untranslated region a sequence which causes inclusion of seleno-
cysteine
CC   residues at a TGA codon within the deiodinase gene. The product of
the
CC   human gene and antibodies reacting with it, are useful in the
diagnosis
CC   and treatment of disease states related to thyroid function. Mutant
```